Future Savings from Measles Eradication in Industrialized Countries

Open Access
Publisher Website
Google Scholar
Abstract
Estimates are made of monetary savings associated with measles eradication in seven industrialized countries. Three scenarios were studied: First, changing from the present two‐dose measles‐mumps‐rubella (MMR) immunization schedule to one‐dose of MMR; second, the use of an MMR and mumps‐rubella schedule; or third, continuing the present schedule. Results show that the largest savings (US $623 million) would be achieved by changing to a one‐dose MMR schedule with an assumption of a 3% discount rate and measles eradication in 2010. The smallest overall savings would result from option 3, by use of a 5% discount rate and the assumption that measles eradication occurs in 2020 ($10 million). These savings are less than previously estimated for the United States, partly because of the assumption that measles vaccines will continue to be delivered in response to possible bioterrorism threats.